EP4463456A4 - THIAZOLOPYRIDYLAMIDE DERIVATIVES AS DNA POLYMERASE ANTA INHIBITORS - Google Patents
THIAZOLOPYRIDYLAMIDE DERIVATIVES AS DNA POLYMERASE ANTA INHIBITORSInfo
- Publication number
- EP4463456A4 EP4463456A4 EP23740050.2A EP23740050A EP4463456A4 EP 4463456 A4 EP4463456 A4 EP 4463456A4 EP 23740050 A EP23740050 A EP 23740050A EP 4463456 A4 EP4463456 A4 EP 4463456A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- thiazolopyridylamide
- anta
- inhibitors
- derivatives
- dna polymerase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022071563 | 2022-01-12 | ||
| PCT/CN2023/071799 WO2023134708A1 (en) | 2022-01-12 | 2023-01-11 | Thiazolopyridyl amide derivatives as dna polymerase theta inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4463456A1 EP4463456A1 (en) | 2024-11-20 |
| EP4463456A4 true EP4463456A4 (en) | 2025-10-29 |
Family
ID=87280119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP23740050.2A Pending EP4463456A4 (en) | 2022-01-12 | 2023-01-11 | THIAZOLOPYRIDYLAMIDE DERIVATIVES AS DNA POLYMERASE ANTA INHIBITORS |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250026766A1 (en) |
| EP (1) | EP4463456A4 (en) |
| JP (1) | JP2025502172A (en) |
| CN (1) | CN118510778A (en) |
| TW (1) | TW202329955A (en) |
| WO (1) | WO2023134708A1 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201700814D0 (en) | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| EP4464709A4 (en) * | 2022-01-13 | 2025-12-24 | Nanjing Zaiming Pharmaceutical Co Ltd | SIX-MOUNT CYCLOTHIAZOLE COMPOUND AND USES THEREOF |
| KR20250092184A (en) | 2022-10-28 | 2025-06-23 | 항저우 신알엑스 테라퓨틱스 바이오메디컬 테크놀로지 컴퍼니 리미티드 | Fused ring nitrogen-containing compounds, intermediates thereof, methods for their preparation and uses |
| CN120152972A (en) * | 2022-11-10 | 2025-06-13 | 北京丹擎医药科技有限公司 | Thiadiazole derivatives and their compositions and uses |
| KR20250153866A (en) | 2023-03-10 | 2025-10-27 | 브레이크포인트 테라퓨틱스 게엠베하 | DNA polymerase theta inhibitor |
| PE20260291A1 (en) | 2023-04-05 | 2026-02-10 | Moma Therapeutics Inc | SEMI-SATURATED BICYCLE DERIVATIVES AND RELATED USES |
| AU2024254066A1 (en) * | 2023-04-05 | 2025-10-16 | Moma Therapeutics, Inc. | Biaryl derivatives and related uses |
| WO2024230578A1 (en) * | 2023-05-05 | 2024-11-14 | Danatlas Pharmaceuticals Co., Ltd. | Cyclic derivatives, compositions and uses thereof |
| CN119306741A (en) * | 2023-07-12 | 2025-01-14 | 杭州圣域生物医药科技有限公司 | Cyclic heteroaromatic compounds, intermediates thereof, preparation methods and applications |
| CN121532193A (en) * | 2023-07-12 | 2026-02-13 | 先声再明医药股份有限公司 | Use of a compound for the prevention or treatment of cancers with defects in the 53BP1/Shieldin complex. |
| WO2025113605A1 (en) * | 2023-12-01 | 2025-06-05 | Ningbo Newbay Technology Development Co., Ltd. | Helicase bicycle amides derivatives and use thereof |
| CN122295094A (en) * | 2023-12-08 | 2026-06-26 | 北京丹擎医药科技有限公司 | Combination therapy of PolQ inhibitors and anticancer drugs |
| AU2025205783A1 (en) * | 2024-01-05 | 2026-07-23 | Daewoong Pharmaceutical Co., Ltd. | Novel heterocyclic compounds and pharmaceutical composition comprising the same |
| WO2025201413A1 (en) * | 2024-03-26 | 2025-10-02 | 上海湃隆生物科技有限公司 | Selenium-containing heterocyclic compound and use thereof |
| WO2025223472A1 (en) * | 2024-04-24 | 2025-10-30 | 杭州圣域生物医药科技有限公司 | Preparation method for fused ring nitrogen-containing compound and intermediate thereof |
| WO2025223471A1 (en) * | 2024-04-24 | 2025-10-30 | 杭州圣域生物医药科技有限公司 | Preparation method for fused-ring nitrogen-containing compound and intermediate thereof |
| CN122055370A (en) * | 2024-04-24 | 2026-05-15 | 杭州圣域生物医药科技有限公司 | And cyclic nitrogen-containing compound, crystal form thereof, preparation method and application thereof |
| WO2025223470A1 (en) * | 2024-04-26 | 2025-10-30 | 杭州圣域生物医药科技有限公司 | Use of polq inhibitor in preparation of drug for treating or preventing tumor |
| WO2026046303A1 (en) * | 2024-08-30 | 2026-03-05 | 杭州圣域生物医药科技有限公司 | COMBINATION OF POLθ INHIBITOR AND PARP INHIBITOR AND USE THEREOF |
| WO2026067816A1 (en) * | 2024-09-30 | 2026-04-02 | 正大天晴药业集团股份有限公司 | Compound containing thiazolo ring structure |
| KR20260105834A (en) * | 2024-10-11 | 2026-07-07 | 아벨로스테라퓨틱스 주식회사 | Seleno-fused heterocyclic compound derivatives and their pharmaceutical uses |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020243459A1 (en) * | 2019-05-31 | 2020-12-03 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors |
| WO2021242955A1 (en) * | 2020-05-28 | 2021-12-02 | Senda Biosciences, Inc. | Fused azole heterocycles as ahr antagonists |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006071035A1 (en) * | 2004-12-31 | 2006-07-06 | Lg Life Sciences, Ltd. | Novel ([1,3]thiazolo[5,4-b]pyridin-2-yl)-2-carboxamide derivatives |
| PE20080888A1 (en) * | 2006-10-18 | 2008-08-26 | Novartis Ag | HETEROCYCLIC COMPOUNDS AS ACIL-TRANSFERASE INHIBITORS OF ACIL-CoA-DIACIL-GLYCEROL 1 (DGAT1) |
| JP2010138073A (en) * | 2007-03-30 | 2010-06-24 | Taisho Pharmaceutical Co Ltd | Picolinic acid amide compound |
| WO2019141980A1 (en) * | 2018-01-17 | 2019-07-25 | Globachem Nv | Agricultural chemicals |
| GB202001181D0 (en) * | 2020-01-28 | 2020-03-11 | Globachem Nv | Agricultural Chemicals |
-
2023
- 2023-01-11 TW TW112101136A patent/TW202329955A/en unknown
- 2023-01-11 EP EP23740050.2A patent/EP4463456A4/en active Pending
- 2023-01-11 WO PCT/CN2023/071799 patent/WO2023134708A1/en not_active Ceased
- 2023-01-11 JP JP2024541677A patent/JP2025502172A/en active Pending
- 2023-01-11 CN CN202380016498.8A patent/CN118510778A/en active Pending
-
2024
- 2024-07-02 US US18/761,919 patent/US20250026766A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020243459A1 (en) * | 2019-05-31 | 2020-12-03 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors |
| WO2021242955A1 (en) * | 2020-05-28 | 2021-12-02 | Senda Biosciences, Inc. | Fused azole heterocycles as ahr antagonists |
Non-Patent Citations (2)
| Title |
|---|
| ZATREANU DIANA ET AL: "Pol[theta] inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance", NATURE COMMUNICATIONS, 17 June 2021 (2021-06-17), London, pages 3636 - 3636, XP055847098, Retrieved from the Internet <URL:https://www.nature.com/articles/s41467-021-23463-8.pdf> [retrieved on 20211004], DOI: 10.1038/s41467-021-23463-8 * |
| ZHOU JIA ET AL: "A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors", NATURE CANCER, vol. 2, no. 6, 17 June 2021 (2021-06-17), pages 598 - 610, XP093087790, Retrieved from the Internet <URL:https://www.nature.com/articles/s43018-021-00203-x> DOI: 10.1038/s43018-021-00203-x * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20250026766A1 (en) | 2025-01-23 |
| TW202329955A (en) | 2023-08-01 |
| JP2025502172A (en) | 2025-01-24 |
| EP4463456A1 (en) | 2024-11-20 |
| WO2023134708A1 (en) | 2023-07-20 |
| CN118510778A (en) | 2024-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4216951A4 (en) | KRAS-G12D INHIBITORS | |
| IL304334A (en) | Modified double-stranded oligonucleotides | |
| EP4197538A4 (en) | EGFR INHIBITORS | |
| PL4363406T3 (en) | NLRP3 INFLAMASOME INHIBITORS | |
| EP4189086A4 (en) | PURIFICATION OF SULFONATED DNA | |
| IL261015B (en) | History of methylamine as lysyl oxidase inhibitors for cancer treatment | |
| IL283775A (en) | Trilop-containing double-stranded nucleic acid inhibitory molecules | |
| EP4182301C0 (en) | AMIDOCYCLOHEXANOIC ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | |
| EP4149629C0 (en) | PURINE DERIVATIVES AS SIK-3 INHIBITORS | |
| EP3946288A4 (en) | SUBSTITUTED 5-CYCLOPROPYL-1H-PYRAZOLE-3-YL-AMINE DERIVATIVES AS SELECTIVE CDK12/13 INHIBITORS | |
| PL4182308T3 (en) | Pyridazinylamine derivatives as ALK5 inhibitors | |
| EP4153596A4 (en) | NEW DIACYLGLYCERIDE-O-ACYLTRANSFERASE-2 INHIBITORS | |
| EP4359402C0 (en) | IMIDAZOLO-INDAZOLE COMPOUNDS AS JAK Inhibitors | |
| EP4452967A4 (en) | SARS-CoV-2 inhibitors | |
| KR102493424B9 (en) | RNA detection method | |
| EP4247372A4 (en) | PLASMAKALLIK INHIBITORS | |
| EP4281457A4 (en) | PYRIDOPYRIMIDE DERIVATIVES AS KRAS INHIBITORS | |
| EP4251273C0 (en) | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | |
| EP4392415A4 (en) | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | |
| PL4228755T3 (en) | TETRAZOLE DERIVATIVES AS TRPA1 INHIBITORS | |
| EP4210694A4 (en) | PLASMAKALLIK INHIBITORS | |
| EP4178620A4 (en) | PLASMAKALLIK INHIBITORS | |
| EP4387965A4 (en) | ARYLSULFONYL COMPOUNDS AS CCR6 INHIBITORS | |
| EP4128186A4 (en) | REDUCING DRIVING RISK | |
| EP4405334C0 (en) | SORTILIN INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20240708 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20250925 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 471/04 20060101AFI20250919BHEP Ipc: C07D 487/04 20060101ALI20250919BHEP Ipc: C07D 498/04 20060101ALI20250919BHEP Ipc: C07D 513/04 20060101ALI20250919BHEP Ipc: A61K 31/437 20060101ALI20250919BHEP Ipc: A61P 35/00 20060101ALI20250919BHEP Ipc: A61K 31/506 20060101ALI20250919BHEP Ipc: A61K 31/5377 20060101ALI20250919BHEP Ipc: C07D 401/14 20060101ALI20250919BHEP Ipc: C07D 413/14 20060101ALI20250919BHEP Ipc: C07D 417/14 20060101ALI20250919BHEP Ipc: C07D 519/00 20060101ALI20250919BHEP |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BEONE MEDICINES I GMBH |